Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 94 entries
Sorted by: Best Match Show Resources per page
[Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon.

Revista iberoamericana de micologia

Fernández-Rivero ME, Del Pozo JL, Valentín A, Fornes V, Molina de Diego A, Pemán J, Cantón E.
PMID: 28601403
Rev Iberoam Micol. 2017 Jul - Sep;34(3):175-179. doi: 10.1016/j.riam.2017.01.002. Epub 2017 Jun 16.

BACKGROUND: Current therapeutic strategies have a limited efficacy against Candida biofilms that form on the surfaces of biomedical devices. Few studies have evaluated the activity of antifungal agents against Candida tropicalis biofilms.OBJECTIVES: To evaluate the activity of amphotericin B...

Cite
Fernández-Rivero ME, Del Pozo JL, Valentín A, et al. Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Rev Iberoam Micol. 2017;34(3):175-179doi: 10.1016/j.riam.2017.01.002.
Fernández-Rivero, M. E., Del Pozo, J. L., Valentín, A., Fornes, V., Molina de Diego, A., Pemán, J., & Cantón, E. (2017). Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Revista iberoamericana de micologia, 34(3), 175-179. https://doi.org/10.1016/j.riam.2017.01.002
Fernández-Rivero, Marcelo Ernesto, et al. "Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon" [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Revista iberoamericana de micologia vol. 34,3 (2017): 175-179. doi: https://doi.org/10.1016/j.riam.2017.01.002
Fernández-Rivero ME, Del Pozo JL, Valentín A, Fornes V, Molina de Diego A, Pemán J, Cantón E. Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Rev Iberoam Micol. 2017 Jul - Sep;34(3):175-179. doi: 10.1016/j.riam.2017.01.002. Epub 2017 Jun 16. Spanish. PMID: 28601403.
Copy Download .nbib Format: NLM
Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review.

Medical mycology case reports

Parcell BJ, B C Raju PK, Johnson EM, Fardon TC, Olver WJ.
PMID: 24624325
Med Mycol Case Rep. 2014 Feb 10;4:12-5. doi: 10.1016/j.mmcr.2014.01.003. eCollection 2014 Apr.

The use of extracorporeal membrane oxygenation (ECMO) for reversible pulmonary failure in critically ill patients has increased over the last few decades. Nosocomial infections are a major complication of ECMO and fungi have been found to be a common...

Cite
Parcell BJ, B C Raju PK, Johnson EM, et al. Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review. Med Mycol Case Rep. 2014;4:12-5doi: 10.1016/j.mmcr.2014.01.003.
Parcell, B. J., B C Raju, P. K., Johnson, E. M., Fardon, T. C., & Olver, W. J. (2014). Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review. Medical mycology case reports, 412-5. https://doi.org/10.1016/j.mmcr.2014.01.003
Parcell, Benjamin J, et al. "Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review." Medical mycology case reports vol. 4 (2014): 12-5. doi: https://doi.org/10.1016/j.mmcr.2014.01.003
Parcell BJ, B C Raju PK, Johnson EM, Fardon TC, Olver WJ. Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review. Med Mycol Case Rep. 2014 Feb 10;4:12-5. doi: 10.1016/j.mmcr.2014.01.003. eCollection 2014 Apr. PMID: 24624325; PMCID: PMC3950536.
Copy Download .nbib Format: NLM
Erratum: Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production.

Medical mycology

[No authors listed]
PMID: 27297085
Med Mycol. 2016 Aug 01;54(6):668. doi: 10.1093/mmy/myw048. Epub 2016 Jun 13.

No abstract available.

Cite
Erratum: Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production. Med Mycol. 2016;54(6):668doi: 10.1093/mmy/myw048.
(2016). Erratum: Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production. Medical mycology, 54(6), 668. https://doi.org/10.1093/mmy/myw048
"Erratum: Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production." Medical mycology vol. 54,6 (2016): 668. doi: https://doi.org/10.1093/mmy/myw048
Erratum: Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production. Med Mycol. 2016 Aug 01;54(6):668. doi: 10.1093/mmy/myw048. Epub 2016 Jun 13. PMID: 27297085.
Copy Download .nbib Format: NLM
Human mycoses and advances in antifungal therapy.

Drug news & perspectives

Fromtling RA.
PMID: 12819825
Drug News Perspect. 2001 Apr;14(3):181-92.

The 11th Focus on Fungal Infections meeting was held in Washington, D.C., U.S.A., March 1416, 2001. At the conference, there were well-attended sessions that focused on the pathogenesis and therapy of fungal disease. This report focuses on new information...

Cite
Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect. 2001;14(3):181-92
Fromtling, R. A. (2001). Human mycoses and advances in antifungal therapy. Drug news & perspectives, 14(3), 181-92.
Fromtling, R A. "Human mycoses and advances in antifungal therapy." Drug news & perspectives vol. 14,3 (2001): 181-92.
Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect. 2001 Apr;14(3):181-92. PMID: 12819825.
Copy Download .nbib Format: NLM
Comparison of echinocandin antifungals.

Therapeutics and clinical risk management

Eschenauer G, Depestel DD, Carver PL.
PMID: 18360617
Ther Clin Risk Manag. 2007 Mar;3(1):71-97. doi: 10.2147/tcrm.2007.3.1.71.

The incidence of invasive fungal infections, especially those due to Aspergillus spp. and Candida spp., continues to increase. Despite advances in medical practice, the associated mortality from these infections continues to be substantial. The echinocandin antifungals provide clinicians with...

Cite
Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3(1):71-97doi: 10.2147/tcrm.2007.3.1.71.
Eschenauer, G., Depestel, D. D., & Carver, P. L. (2007). Comparison of echinocandin antifungals. Therapeutics and clinical risk management, 3(1), 71-97. https://doi.org/10.2147/tcrm.2007.3.1.71
Eschenauer, Gregory, et al. "Comparison of echinocandin antifungals." Therapeutics and clinical risk management vol. 3,1 (2007): 71-97. doi: https://doi.org/10.2147/tcrm.2007.3.1.71
Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007 Mar;3(1):71-97. doi: 10.2147/tcrm.2007.3.1.71. PMID: 18360617; PMCID: PMC1936290.
Copy Download .nbib Format: NLM
Echinocandins: A ray of hope in antifungal drug therapy.

Indian journal of pharmacology

Grover ND.
PMID: 20606829
Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396.

Invasive fungal infections are on the rise. Amphotericin B and azole antifungals have been the mainstay of antifungal therapy so far. The high incidence of infusion related toxicity and nephrotoxicity with amphotericin B and the emergence of fluconazole resistant...

Cite
Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010;42(1):9-11doi: 10.4103/0253-7613.62396.
Grover, N. D. (2010). Echinocandins: A ray of hope in antifungal drug therapy. Indian journal of pharmacology, 42(1), 9-11. https://doi.org/10.4103/0253-7613.62396
Grover, Neeta D. "Echinocandins: A ray of hope in antifungal drug therapy." Indian journal of pharmacology vol. 42,1 (2010): 9-11. doi: https://doi.org/10.4103/0253-7613.62396
Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396. PMID: 20606829; PMCID: PMC2885632.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16082427
Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(4):265-84
Bayes, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(4), 265-84.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,4 (2005): 265-84.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84. PMID: 16082427.
Copy Download .nbib Format: NLM
Invasive fungal infections in infants-focus on anidulafungin.

Clinical medicine insights. Pediatrics

Wilke MH.
PMID: 23641173
Clin Med Insights Pediatr. 2013 Feb 07;7:7-11. doi: 10.4137/CMPed.S8028. Print 2013.

INTRODUCTION: Invasive fungal infection in pediatric intensive care units (PICU) is a rising challenge. Candida species are the most common microorganisms in these infections. Due to growing resistance against fluconazole, echinocandins are being used for the appropriate therapy. However,...

Cite
Wilke MH. Invasive fungal infections in infants-focus on anidulafungin. Clin Med Insights Pediatr. 2013;7:7-11doi: 10.4137/CMPed.S8028.
Wilke, M. H. (2013). Invasive fungal infections in infants-focus on anidulafungin. Clinical medicine insights. Pediatrics, 77-11. https://doi.org/10.4137/CMPed.S8028
Wilke, Michael H. "Invasive fungal infections in infants-focus on anidulafungin." Clinical medicine insights. Pediatrics vol. 7 (2013): 7-11. doi: https://doi.org/10.4137/CMPed.S8028
Wilke MH. Invasive fungal infections in infants-focus on anidulafungin. Clin Med Insights Pediatr. 2013 Feb 07;7:7-11. doi: 10.4137/CMPed.S8028. Print 2013. PMID: 23641173; PMCID: PMC3620775.
Copy Download .nbib Format: NLM
Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis.

GMS infectious diseases

Schmalreck AF, Willinger B, Idelevich EA, Fegeler C, Lass-Flörl C, Fegeler W, Becker K.
PMID: 30671316
GMS Infect Dis. 2016 Jun 07;4:Doc02. doi: 10.3205/id000020. eCollection 2016.

For calculated initial antifungal therapy, knowledge on parallel and cross-resistances are vitally important particularly in the case of multiresistant isolates. Based on a strain collection of 1,062 yeast isolates from a German/Austrian multicentre study, susceptibility pattern analysis (SPA) was...

Cite
Schmalreck AF, Willinger B, Idelevich EA, et al. Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis. GMS Infect Dis. 2016;4:Doc02doi: 10.3205/id000020.
Schmalreck, A. F., Willinger, B., Idelevich, E. A., Fegeler, C., Lass-Flörl, C., Fegeler, W., & Becker, K. (2016). Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis. GMS infectious diseases, 4Doc02. https://doi.org/10.3205/id000020
Schmalreck, Arno F, et al. "Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis." GMS infectious diseases vol. 4 (2016): Doc02. doi: https://doi.org/10.3205/id000020
Schmalreck AF, Willinger B, Idelevich EA, Fegeler C, Lass-Flörl C, Fegeler W, Becker K. Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis. GMS Infect Dis. 2016 Jun 07;4:Doc02. doi: 10.3205/id000020. eCollection 2016. PMID: 30671316; PMCID: PMC6301743.
Copy Download .nbib Format: NLM
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain.

ClinicoEconomics and outcomes research : CEOR

Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, Heinz WJ, Barrueta JA, Peral C, Mesa FJ, Barrado M, Charbonneau C, Rubio-Rodríguez D, Rubio-Terrés C.
PMID: 28115858
Clinicoecon Outcomes Res. 2016 Dec 30;9:39-47. doi: 10.2147/CEOR.S122177. eCollection 2017.

OBJECTIVE: According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, mortality was lower after...

Cite
Grau S, Azanza JR, Ruiz I, et al. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. Clinicoecon Outcomes Res. 2016;9:39-47doi: 10.2147/CEOR.S122177.
Grau, S., Azanza, J. R., Ruiz, I., Vallejo, C., Mensa, J., Maertens, J., Heinz, W. J., Barrueta, J. A., Peral, C., Mesa, F. J., Barrado, M., Charbonneau, C., Rubio-Rodríguez, D., & Rubio-Terrés, C. (2017). Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and outcomes research : CEOR, 939-47. https://doi.org/10.2147/CEOR.S122177
Grau, Santiago, et al. "Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain." ClinicoEconomics and outcomes research : CEOR vol. 9 (2017): 39-47. doi: https://doi.org/10.2147/CEOR.S122177
Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, Heinz WJ, Barrueta JA, Peral C, Mesa FJ, Barrado M, Charbonneau C, Rubio-Rodríguez D, Rubio-Terrés C. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. Clinicoecon Outcomes Res. 2016 Dec 30;9:39-47. doi: 10.2147/CEOR.S122177. eCollection 2017. PMID: 28115858; PMCID: PMC5221484.
Copy Download .nbib Format: NLM
Recent Insights into the Paradoxical Effect of Echinocandins.

Journal of fungi (Basel, Switzerland)

Wagener J, Loiko V.
PMID: 29371498
J Fungi (Basel). 2017 Dec 28;4(1). doi: 10.3390/jof4010005.

Echinocandin antifungals represent one of the most important drug classes for the treatment of invasive fungal infections. The mode of action of the echinocandins relies on inhibition of the β-1,3-glucan synthase, an enzyme essentially required for the synthesis of...

Cite
Wagener J, Loiko V. Recent Insights into the Paradoxical Effect of Echinocandins. J Fungi (Basel). 2017;4(1)doi: 10.3390/jof4010005.
Wagener, J., & Loiko, V. (2017). Recent Insights into the Paradoxical Effect of Echinocandins. Journal of fungi (Basel, Switzerland), 4(1), . https://doi.org/10.3390/jof4010005
Wagener, Johannes, and Loiko, Veronika. "Recent Insights into the Paradoxical Effect of Echinocandins." Journal of fungi (Basel, Switzerland) vol. 4,1 (2017). doi: https://doi.org/10.3390/jof4010005
Wagener J, Loiko V. Recent Insights into the Paradoxical Effect of Echinocandins. J Fungi (Basel). 2017 Dec 28;4(1). doi: 10.3390/jof4010005. PMID: 29371498; PMCID: PMC5872308.
Copy Download .nbib Format: NLM
Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?.

Current fungal infection reports

Novak AR, Bradley ME, Kiser TH, Mueller SW.
PMID: 32699568
Curr Fungal Infect Rep. 2020 Jun;14(2):141-152. doi: 10.1007/s12281-020-00379-2. Epub 2020 Mar 26.

PURPOSE OF REVIEW: This review summarizes current treatment options for echinocandin-resistant RECENT FINDINGS: Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide...

Cite
Novak AR, Bradley ME, Kiser TH, et al. Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?. Curr Fungal Infect Rep. 2020;14(2):141-152doi: 10.1007/s12281-020-00379-2.
Novak, A. R., Bradley, M. E., Kiser, T. H., & Mueller, S. W. (2020). Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?. Current fungal infection reports, 14(2), 141-152. https://doi.org/10.1007/s12281-020-00379-2
Novak, Alison R, et al. "Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?." Current fungal infection reports vol. 14,2 (2020): 141-152. doi: https://doi.org/10.1007/s12281-020-00379-2
Novak AR, Bradley ME, Kiser TH, Mueller SW. Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?. Curr Fungal Infect Rep. 2020 Jun;14(2):141-152. doi: 10.1007/s12281-020-00379-2. Epub 2020 Mar 26. PMID: 32699568; PMCID: PMC7375389.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 94 entries